Home
Drugs
Bevacizumab
Clinical Trials

Clinical Trials Related to Bevacizumab

Related studies linked through entity extraction aliases.

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Status: RECRUITING
Phase: PHASE1

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Status: RECRUITING
Phase: PHASE2

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Status: RECRUITING
Phase: PHASE2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Status: RECRUITING
Phase: PHASE1/PHASE2

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Status: COMPLETED
Phase: N/A

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Status: RECRUITING
Phase: PHASE4

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Status: RECRUITING
Phase: PHASE2

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

Status: UNKNOWN
Phase: PHASE2

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Status: TERMINATED
Phase: PHASE2

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2/PHASE3